Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
synthetic cannabinoid
|
| gptkbp:actsOn |
CB1 receptor agonist
CB2 receptor agonist |
| gptkbp:CASNumber |
208987-48-8
|
| gptkbp:category |
gptkb:naphthoylindole
recreational drug |
| gptkbp:chemicalFormula |
C23H21NO
|
| gptkbp:discoveredBy |
gptkb:John_W._Huffman
|
| gptkbp:firstSynthesized |
1990s
|
| gptkbp:has_psychoactive_effects |
yes
|
| gptkbp:hasSMILES |
CCCCN1C=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43
|
| https://www.w3.org/2000/01/rdf-schema#label |
JWH-073
|
| gptkbp:IUPACName |
naphthalen-1-yl-(1-butylindol-3-yl)methanone
|
| gptkbp:legalStatus |
Class B drug (UK)
Schedule I controlled substance (US) |
| gptkbp:molecularWeight |
327.42 g/mol
|
| gptkbp:namedAfter |
gptkb:John_W._Huffman
|
| gptkbp:PubChem_CID |
44418354
|
| gptkbp:relatedTo |
gptkb:JWH-018
gptkb:JWH-122 |
| gptkbp:routeOfAdministration |
smoking
oral inhalation |
| gptkbp:UNII |
6K3F6F0U5T
|
| gptkbp:used_in |
synthetic cannabis products
|
| gptkbp:usedFor |
scientific research
|
| gptkbp:bfsParent |
gptkb:JWH_cannabinoids
|
| gptkbp:bfsLayer |
6
|